Novo Nordisk A/SLong
Novo Nordisk | NVO | Long at $86.74
The Good:
The Bad:
Personally, the positives outweigh the negatives given the obesity drug demand. Thus, at $86.74,NVO is in a personal buy zone.
Targets:
- NVO expects its GLP-1 drugs Wegovy and Ozempic to soon come off the Food and Drug Administration's official shortage list.
- Just reported better-than-expected net profit in Q4 2024, amid soaring demand for its obesity drugs.
- Revenues for the Q4 2024 came in at $11.6 billion, up 30% compared to the same quarter in 2023.
- From a technical analysis perspective, hovering near my historical simple moving average which may lead to a near-term price increase due to positive earnings
The Bad:
- Slower growth in 2025 (16%-24% for 2025 vs 18%-26% in 2024).
- Chart has been on a major run since 2020 and may be due for further correction.
Personally, the positives outweigh the negatives given the obesity drug demand. Thus, at $86.74,
NVO is in a personal buy zone.Targets:
- $96.00
- $105.00
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.